The FDA approves Axonics Modulation Technologies’ (NASDAQ:AXNX) Axonics r-SNM System for clinical indications of overactive bladder and urinary retention.
The rechargeable device modulates the sacral nerves that control muscles and organs that contribute to bladder control.
The company will host a conference call today at 4:30 pm ET to discuss Q3 results and recent business developments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.